Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346165 | 1.00 | BACE1 (0.46) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL6349287 | 0.92 | BACE1 (0.45) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL7205505 | 0.87 | BACE1 (0.45) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL6353989 | 0.87 | BACE1 (0.45) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL31340321 | 0.85 | BACE1 (0.45) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL5432734 | 0.85 | BACE1 (0.43) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL5432743 | 0.85 | BACE1 (0.43) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL5432737 | 0.85 | BACE1 (0.43) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL5432591 | 0.84 | BACE1 (0.44) | BACE1KDM4EPKMUSP30KMT2A | |
| SCHEMBL4688249 | 0.84 | BACE1 (0.44) | BACE1KDM4EPKMUSP30KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
| US-7858737-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | BACE1 54/4885KDM4E 4717/4885PKM 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.